HomeAI · summaries
Storia in 3 fonti
Dr Reddy's delays semaglutide supply due to active ingredient issue
Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Wegovy, Ozempic regain weight as Indian generics fall behind
Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth, unlike generics. Eli Lilly's…
- ·
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient…
